{"protocolSection": {"identificationModule": {"nctId": "NCT00423878", "orgStudyIdInfo": {"id": "STROUP06STN0"}, "secondaryIdInfos": [{"id": "DSIR AT-AP", "type": "OTHER", "domain": "National Institute of Mental Health"}], "organization": {"fullName": "National Institute of Mental Health (NIMH)", "class": "NIH"}, "briefTitle": "Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder", "officialTitle": "Clinical Management of Metabolic Problems in Patients With Schizophrenia", "acronym": "CAMP"}, "statusModule": {"statusVerifiedDate": "2010-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-01-16", "studyFirstSubmitQcDate": "2007-01-16", "studyFirstPostDateStruct": {"date": "2007-01-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-11-16", "resultsFirstSubmitQcDate": "2012-11-16", "resultsFirstPostDateStruct": {"date": "2012-12-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-27", "lastUpdatePostDateStruct": {"date": "2016-11-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "National Institute of Mental Health (NIMH)", "class": "NIH"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease.", "detailedDescription": "Metabolic abnormalities associated with cardiovascular morbidity and premature mortality are more common in patients with schizophrenia than in matched controls. Although there is some evidence that patients with schizophrenia have intrinsic abnormalities in lipid and carbohydrate metabolism, some antipsychotics (i.e., clozapine, olanzapine, quetiapine, and risperidone) are associated with increased rates of metabolic abnormalities that predispose patients to cardiovascular disease.\n\nThis is an investigator-initiated clinical trial that will be conducted at 30 research sites that are a part of the NIMH Schizophrenia Trials Network.\n\nThe aims of the study are to (1) determine the relative effects of switching to aripiprazole, versus continued treatment with olanzapine, quetiapine, or risperidone, on metabolic parameters associated with cardiovascular disease, and (2) to determine the effects of switching to aripiprazole versus continued treatment with olanzapine, quetiapine, or risperidone on the clinical stability of schizophrenic illness.\n\nThis study design is a multi-site, single-blind (rater) randomized controlled trial of 300 patients with schizophrenia or schizoaffective disorder comparing treatment with the following medications: olanzapine, quetiapine, risperidone, and aripiprazole. The study will enroll patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease in spite of adequate control of symptoms on their current antipsychotic medication. Patients who are taking olanzapine, quetiapine, or risperidone and who have a body-mass index (BMI) greater than or equal to 27 and non-HDL cholesterol greater than or equal to 130 mg/dl will be eligible (if non-HDL is between 130-139mg/dL, LDL cholesterol must be greater than 100mg/dL). All treatments will be open label. Raters will be blinded to treatment assignment. Patients will be followed for up to 6 months."}, "conditionsModule": {"conditions": ["Schizophrenia", "Schizoaffective Disorder"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 215, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day", "interventionNames": ["Drug: Aripiprazole"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.", "interventionNames": ["Drug: Risperidone", "Drug: Olanzapine", "Drug: Quetiapine"]}], "interventions": [{"type": "DRUG", "name": "Risperidone", "description": "Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study", "armGroupLabels": ["2"], "otherNames": ["Risperdal"]}, {"type": "DRUG", "name": "Olanzapine", "description": "Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study", "armGroupLabels": ["2"], "otherNames": ["Zyprexa"]}, {"type": "DRUG", "name": "Quetiapine", "description": "Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study", "armGroupLabels": ["2"], "otherNames": ["Seroquel"]}, {"type": "DRUG", "name": "Aripiprazole", "description": "Switching medication to aripiprazole for schizophrenia for up to 6 months in study", "armGroupLabels": ["1"], "otherNames": ["Abilify"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks", "description": "Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis.", "timeFrame": "24 weeks"}], "secondaryOutcomes": [{"measure": "Efficacy Failure, Defined as Psychiatric Hospitalization, a 25 Percent Increase From Baseline on the Positive and Negative Syndrome Scale or Substantial Clinical Deterioration on the Clinical Global Impressions-Change (CGI-C)", "timeFrame": "Measured at Month 6"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with schizophrenia or schizoaffective disorder\n* Currently treated with olanzapine, quetiapine or risperidone\n* BMI greater than or equal to 27\n* Non-HDL cholesterol greater than or equal to 130 mg/dL (if non-HDL cholesterol is between 130 - 139 mg/dL, then LDL cholesterol must be greater than 100 mg/dL).\n\nExclusion Criteria:\n\n* Diabetes (FBS greater than or equal to 126) or treatment with oral hypoglycemic drug or insulin\n* Non-HDL cholesterol greater than 300 mg/dL\n* Serum triglycerides greater than 500 mg/dL\n* Patients in the first episode of schizophrenia or schizoaffective disorder\n* Known hypersensitivity to aripiprazole\n* On weight loss medications", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "T. Scott Stroup, MD, MPH", "affiliation": "Columbia University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Joseph P. McEvoy, MD", "affiliation": "Duke University", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "SHANTI Clinical Trials", "city": "Colton", "state": "California", "zip": "92324", "country": "United States", "geoPoint": {"lat": 34.0739, "lon": -117.31365}}, {"facility": "Stanford University", "city": "Palo Alto", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.44188, "lon": -122.14302}}, {"facility": "Yale University", "city": "New Haven", "state": "Connecticut", "zip": "06519", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Mental Health Advocates", "city": "Boca Raton", "state": "Florida", "zip": "33431", "country": "United States", "geoPoint": {"lat": 26.3669, "lon": -80.13033}}, {"facility": "University of Miami School of Medicine", "city": "Miami", "state": "Florida", "zip": "33316", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30329", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Medical College of Georgia", "city": "Augusta", "state": "Georgia", "zip": "30912", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "University of Iowa", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Clinical Research Institute", "city": "Wichita", "state": "Kansas", "zip": "67207", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "Lousiana State University Health Sciences Center", "city": "Shreveport", "state": "Louisiana", "zip": "71130", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "Clinical Insights", "city": "Glen Burnie", "state": "Maryland", "zip": "21061", "country": "United States", "geoPoint": {"lat": 39.16261, "lon": -76.62469}}, {"facility": "Freedom Trail Clinic", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "John C Corrigan Community Mental Health Center", "city": "Fall River", "state": "Massachusetts", "zip": "02720", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "University of Massachusetts", "city": "Worcester", "state": "Massachusetts", "zip": "01605", "country": "United States", "geoPoint": {"lat": 42.26259, "lon": -71.80229}}, {"facility": "Wayne State University", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "University of Minnesota", "city": "Minneapolis", "state": "Minnesota", "zip": "55454", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Washington University School of Medicine", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "New Mexico VA Healthcare System", "city": "Albuquerque", "state": "New Mexico", "zip": "87108", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Foundation for Mental Hygiene", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "University of Rochester", "city": "Rochester", "state": "New York", "zip": "14623", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "John Umstead Hospital/Duke University", "city": "Butner", "state": "North Carolina", "zip": "27509", "country": "United States", "geoPoint": {"lat": 36.13209, "lon": -78.75667}}, {"facility": "The University of North Carolina", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599-7160", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Carolinas HealthCare System", "city": "Charlotte", "state": "North Carolina", "zip": "28211", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "University of Cincinnati", "city": "Cincinnati", "state": "Ohio", "zip": "45267", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Philadelphia VA Medical Center-116A", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "University of Texas Southwestern Medical Center", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "University of Texas Health Science Center at San Antonio", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}]}, "referencesModule": {"references": [{"pmid": "21768610", "type": "BACKGROUND", "citation": "Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Switch Group", "description": "Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day."}, {"id": "FG001", "title": "Stay Group", "description": "Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "109"}, {"groupId": "FG001", "numSubjects": "106"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "89"}, {"groupId": "FG001", "numSubjects": "98"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Switch Group", "description": "Participants will switch to aripiprazole."}, {"id": "BG001", "title": "Stay Group", "description": "Participants will continue treatment with olanzapine, quetiapine, or risperidone."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "215"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "215"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40", "spread": "11.7"}, {"groupId": "BG001", "value": "42", "spread": "10.5"}, {"groupId": "BG002", "value": "41", "spread": "11.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "78"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "137"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "215"}]}]}]}, {"title": "non-HDL cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169", "spread": "31.9"}, {"groupId": "BG001", "value": "176", "spread": "33.5"}, {"groupId": "BG002", "value": "173", "spread": "32.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks", "description": "Change in non-HDL cholesterol measured at baseline and every 4 weeks for 24 weeks. The efficacy analysis corresponded to a comparison of change in non-HDL cholesterol from baseline to 24 weeks between treatment groups (stay versus switch). Repeated measurements mixed effects linear models were fit for the primary analysis.", "populationDescription": "The primary efficacy analysis was conducted on the efficacy evaluable population, defined as all patients randomly assigned to a study group who received at least one dose of study medication and completed at least one post-baseline efficacy assessment.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL non-HDL cholesterol", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Switch Group", "description": "Participants will switch to aripiprazole."}, {"id": "OG001", "title": "Stay Group", "description": "Participants will continue treatment with olanzapine, quetiapine, or risperidone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.2", "spread": "2.87"}, {"groupId": "OG001", "value": "-10.8", "spread": "2.57"}]}]}]}, {"type": "SECONDARY", "title": "Efficacy Failure, Defined as Psychiatric Hospitalization, a 25 Percent Increase From Baseline on the Positive and Negative Syndrome Scale or Substantial Clinical Deterioration on the Clinical Global Impressions-Change (CGI-C)", "populationDescription": "2 participants who never took assigned study medication were excluded.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Measured at Month 6", "groups": [{"id": "OG000", "title": "Switch Group", "description": "Participants will switch to aripiprazole."}, {"id": "OG001", "title": "Stay Group", "description": "Participants will continue treatment with olanzapine, quetiapine, or risperidone."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "18"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "description": "Two participants randomized to switch to aripiprazole withdrew from the study before taking the study medication.", "eventGroups": [{"id": "EG000", "title": "Switch Group", "description": "Participants will switch to aripiprazole.", "seriousNumAffected": 18, "seriousNumAtRisk": 107, "otherNumAffected": 77, "otherNumAtRisk": 107}, {"id": "EG001", "title": "Stay Group", "description": "Participants will continue treatment with olanzapine, quetiapine, or risperidone.", "seriousNumAffected": 9, "seriousNumAtRisk": 106, "otherNumAffected": 77, "otherNumAtRisk": 106}], "seriousEvents": [{"term": "Exacerbation of schizophrenia", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 106}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}]}, {"term": "Syncope", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}]}, {"term": "Slurred speech/sedation", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"term": "Suicidality", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 106}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"term": "Agranulocytosis", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"term": "Accidental overdose", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}]}, {"term": "Neuropathic pain", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"term": "Victim of gunshot wound", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 106}]}, {"organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 106}]}], "otherEvents": [{"term": "Insomnia", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 44, "numAffected": 44, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 29, "numAffected": 29, "numAtRisk": 106}]}, {"term": "Sleepiness", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 27, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 35, "numAffected": 35, "numAtRisk": 106}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 24, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 36, "numAffected": 36, "numAtRisk": 106}]}, {"term": "Akathisia/activation", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 29, "numAffected": 29, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 26, "numAffected": 26, "numAtRisk": 106}]}, {"term": "Problems with sex drive", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 24, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 26, "numAffected": 26, "numAtRisk": 106}]}, {"term": "Increased appetite", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 26, "numAffected": 26, "numAtRisk": 106}]}, {"term": "Weight gain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 21, "numAffected": 21, "numAtRisk": 106}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 20, "numAffected": 20, "numAtRisk": 106}]}, {"term": "Akinesia", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 14, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 25, "numAffected": 25, "numAtRisk": 106}]}, {"term": "Problems with sexual orgasm", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 19, "numAffected": 19, "numAtRisk": 106}]}, {"term": "Problems with sexual arousal", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 18, "numAffected": 18, "numAtRisk": 106}]}, {"term": "Hypersomnia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 16, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 21, "numAffected": 21, "numAtRisk": 106}]}, {"term": "Orthostatic faintness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 19, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 18, "numAffected": 18, "numAtRisk": 106}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 12, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 18, "numAffected": 18, "numAtRisk": 106}]}, {"term": "Incontinence/nocturia", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 106}]}, {"term": "Skin rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 106}]}, {"term": "Menstrual irregularities", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 106}]}, {"term": "Sialorrhea", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 106}]}, {"term": "Urinary hesistancy", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 106}]}, {"term": "Gynecomastia/galactorrhea", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 107}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 106}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Open-label treatment is a limitation of this study, particularly for outcomes not measured in the laboratory but instead subject to clinical judgment."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Scott Stroup", "organization": "Columbia University", "email": "stroups@nyspi.columbia.edu", "phone": "212-543-5676"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}, {"id": "D000011618", "term": "Psychotic Disorders"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "asFound": "Schizoaffective Disorder", "relevance": "HIGH"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077152", "term": "Olanzapine"}, {"id": "D000018967", "term": "Risperidone"}, {"id": "D000068180", "term": "Aripiprazole"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000017367", "term": "Selective Serotonin Reuptake Inhibitors"}, {"id": "D000014179", "term": "Neurotransmitter Uptake Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000058825", "term": "Serotonin 5-HT1 Receptor Agonists"}, {"id": "D000017366", "term": "Serotonin Receptor Agonists"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M229", "name": "Aripiprazole", "asFound": "Association", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M1675", "name": "Olanzapine", "asFound": "Cavity", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M19649", "name": "Selective Serotonin Reuptake Inhibitors", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M29240", "name": "Serotonin 5-HT1 Receptor Agonists", "relevance": "LOW"}, {"id": "M19648", "name": "Serotonin Receptor Agonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}